Trade

Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License

Posted on by James Love

Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch’s office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked. Continue Reading →

TRIPS Council March 2016: India reiterates support for de-linkage and references UN High Level Panel on Access to Medicines

Posted on by Thiru

In early March 2016, the World Trade Organization’s (WTO) TRIPS Council discussed “Intellectual Property and Innovation: Education and Diffusion”. The following delegations co-sponsored discussion of this item on Education and Diffusion – Australia, European Union, Switzerland, United States, Japan, Singapore, Peru, Russian Federation, Chinese Taipei and Hong Kong China.

Continue Reading →

US, AU and CA try to block WTO LDC drug patent waiver because PhRMA’s not happy enough with the TPP

Posted on by Thiru

Members of the World Trade Organization (WTO) meet this week in Geneva (15 October 2015 – 16 October 2015) to decide if the poorest countries on earth are exempt from WTO rules for pharmaceutical patents. The WTO’s TRIPS Council is expected to make a decision in respect of the request of the LDC Group’s request for indefinite exemption from TRIPS obligations on pharmaceutical patents. Continue Reading →

July 2015: WTO reports on EU competition policy and copyright law – WTO Trade Policy Review – European Union

Posted on by Thiru

On 6 July 2015 and 8 July 2015, the World Trade Organization (WTO) conducted a trade policy review of the European Union. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). As noted by the WTO secretariat, the “basis for the review is a report by the WTO Secretariat and a report by the Government of the European Union” (Source: Trade Policy Review – European Union, July 2015).

Continue Reading →

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Posted on by Claire Cassedy

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015
Continue Reading →